Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer.

Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, Brown M, Jeselsohn R.

NPJ Breast Cancer. 2018 Aug 2;4:22. doi: 10.1038/s41523-018-0075-5. eCollection 2018.

2.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Aug 2. doi: 10.1001/jamaoncol.2018.2969. [Epub ahead of print]

PMID:
30073261
3.

Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova E, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Janne PA.

Clin Cancer Res. 2018 Aug 2. pii: clincanres.0876.2018. doi: 10.1158/1078-0432.CCR-18-0876. [Epub ahead of print]

PMID:
30072474
4.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA.

Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.

PMID:
30038220
5.

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.

Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP, Oxnard GR.

Lung Cancer. 2018 Aug;122:72-75. doi: 10.1016/j.lungcan.2018.05.024. Epub 2018 May 25.

PMID:
30032849
6.

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays.

Oxnard GR, Paweletz CP.

JAMA Oncol. 2018 Jul 19. doi: 10.1001/jamaoncol.2018.2311. [Epub ahead of print] No abstract available.

PMID:
30027282
7.

Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer.

Hanna GJ, Supplee JG, Kuang Y, Mahmood U, Lau CJ, Haddad RI, Jänne PA, Paweletz CP.

Ann Oncol. 2018 Jul 13. doi: 10.1093/annonc/mdy251. [Epub ahead of print]

PMID:
30010779
8.

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.

Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutiérrez-Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK.

Clin Cancer Res. 2018 Jun 26. doi: 10.1158/1078-0432.CCR-17-3438. [Epub ahead of print]

PMID:
29945997
9.

Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.

Kuang Y, O'Connell A, Sacher AG, Feeney N, Alden RS, Oxnard GR, Paweletz CP.

Methods Mol Biol. 2018;1768:193-207. doi: 10.1007/978-1-4939-7778-9_12.

PMID:
29717445
10.

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies.

Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, Fairclough SR, Zill OA, Sikora M, Mokhtari R, Abdueva D, Nagy RJ, Lee CE, Kiedrowski LA, Paweletz CP, Eltoukhy H, Lanman RB, Chudova DI, Talasaz A.

Clin Cancer Res. 2018 Aug 1;24(15):3539-3549. doi: 10.1158/1078-0432.CCR-17-3831. Epub 2018 Apr 24.

PMID:
29691297
11.

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR.

Clin Cancer Res. 2018 Mar 22. doi: 10.1158/1078-0432.CCR-18-0143. [Epub ahead of print]

PMID:
29567812
12.

Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.

Yanagita M, Luke JJ, Hodi FS, Jänne PA, Paweletz CP.

Melanoma Res. 2018 Apr;28(2):89-95. doi: 10.1097/CMR.0000000000000431.

PMID:
29406397
13.

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.

Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR.

Ann Oncol. 2018 Apr 1;29(4):1049-1055. doi: 10.1093/annonc/mdy005.

PMID:
29325035
14.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

PMID:
29101163
15.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

PMID:
29101162
16.

Cell-Free DNA in Oncology: Gearing up for Clinic.

Ulrich BC, Paweletz CP.

Ann Lab Med. 2018 Jan;38(1):1-8. doi: 10.3343/alm.2018.38.1.1. Review.

17.

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients.

Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR.

Clin Cancer Res. 2017 Dec 1;23(23):7351-7359. doi: 10.1158/1078-0432.CCR-17-1745. Epub 2017 Sep 25.

PMID:
28947568
18.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG.

Oncologist. 2017 Jan;22(1):25-32. doi: 10.1634/theoncologist.2016-0229. Epub 2016 Oct 27.

19.

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, Yuan GC, Kufe DW, Jänne PA, Hammerman PS, Sholl LM, Hodi FS, Richards WG, Bueno R, English JM, Bittinger MA, Wong KK.

JCI Insight. 2016 Sep 8;1(14):e89014.

20.

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR.

Cancer Discov. 2016 Dec;6(12):1334-1341. Epub 2016 Sep 30.

21.

Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer.

Oxnard GR, Paweletz CP, Sholl LM.

JAMA Oncol. 2017 Jun 1;3(6):740-741. doi: 10.1001/jamaoncol.2016.2835. No abstract available.

PMID:
27541382
22.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA.

J Clin Oncol. 2016 Oct 1;34(28):3375-82. doi: 10.1200/JCO.2016.66.7162. Epub 2016 Jun 27.

23.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.

24.

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Barrett C, Yang J, Jänne P.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S154. doi: 10.1016/S1556-0864(16)30328-8. Epub 2016 Apr 15. No abstract available.

25.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR.

Clin Cancer Res. 2016 Feb 15;22(4):915-22. doi: 10.1158/1078-0432.CCR-15-1627-T. Epub 2015 Oct 12.

26.

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.

Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, Kikuchi E, Xu C, Patel TB, Al-Shahrour F, Carretero J, Wong KK, Jänne PA, Shapiro GI, Shimamura T.

Cancer Res. 2015 Oct 15;75(20):4372-83. doi: 10.1158/0008-5472.CAN-15-0377. Epub 2015 Aug 17.

27.

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.

Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP, Seeburger JL, Li J, Meng F, Deyanova EG, Mazur MT, Settlage RE, Zhao X, Southwick K, Du Y, Holder D, Sachs JR, Laterza OF, Dallob A, Chappell DL, Snyder K, Modur V, King E, Joachim C, Bondarenko AY, Shearman M, Soper KA, Smith AD, Potter WZ, Koblan KS, Sachs AB, Yates NA.

PLoS One. 2015 Aug 13;10(8):e0135365. doi: 10.1371/journal.pone.0135365. eCollection 2015.

28.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR.

Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.

29.

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, Johnson BE; Cell Free DNA Working Group.

J Natl Cancer Inst. 2014 Aug 8;106(8). pii: dju214. doi: 10.1093/jnci/dju214. Print 2014 Aug.

PMID:
25106647
30.

Monitoring cancer through the blood.

Paweletz CP, Jänne PA.

Cancer. 2014 Dec 15;120(24):3859-61. doi: 10.1002/cncr.28967. Epub 2014 Aug 7. No abstract available.

31.

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA.

Clin Cancer Res. 2014 Mar 15;20(6):1698-1705. doi: 10.1158/1078-0432.CCR-13-2482. Epub 2014 Jan 15.

32.

Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21.

Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, Dallas-Yang Q, Wu M, Sarr T, Zhu L, Guo H, Li Z, Li W, Hu W, Jiang G, Paweletz CP, Hendrickson RC, Thompson JR, Mu J, Berger JP, Mehmet H.

PLoS One. 2013 Sep 6;8(9):e73011. doi: 10.1371/journal.pone.0073011. eCollection 2013.

33.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK.

Transl Oncol. 2012 Dec;5(6):422-9. Epub 2012 Dec 1.

34.

Identification of direct target engagement biomarkers for kinase-targeted therapeutics.

Paweletz CP, Andersen JN, Pollock R, Nagashima K, Hayashi ML, Yu SU, Guo H, Bobkova EV, Xu Z, Northrup A, Blume-Jensen P, Hendrickson RC, Chi A.

PLoS One. 2011;6(10):e26459. doi: 10.1371/journal.pone.0026459. Epub 2011 Oct 24.

35.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

36.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ.

Cancer Res. 2010 Feb 15;70(4):1524-33. doi: 10.1158/0008-5472.CAN-09-2541. Epub 2010 Feb 9.

37.

Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry.

Paweletz CP, Wiener MC, Bondarenko AY, Yates NA, Song Q, Liaw A, Lee AY, Hunt BT, Henle ES, Meng F, Sleph HF, Holahan M, Sankaranarayanan S, Simon AJ, Settlage RE, Sachs JR, Shearman M, Sachs AB, Cook JJ, Hendrickson RC.

J Proteome Res. 2010 Mar 5;9(3):1392-401. doi: 10.1021/pr900925d.

PMID:
20095649
38.

Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.

Lee AY, Paweletz CP, Pollock RM, Settlage RE, Cruz JC, Secrist JP, Miller TA, Stanton MG, Kral AM, Ozerova ND, Meng F, Yates NA, Richon V, Hendrickson RC.

J Proteome Res. 2008 Dec;7(12):5177-86. doi: 10.1021/pr800510p.

PMID:
19367703
39.

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.

Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, Li L, Gooden F, Korenchuk S, Hou XS, Harrington EA, Randolph S, Reilly JF, Ware CM, Kadin ME, Frankel SR, Richon VM.

Cancer Res. 2008 May 15;68(10):3785-94. doi: 10.1158/0008-5472.CAN-07-6091.

40.

Laser capture microdissection.

Charboneau L, Paweletz CP, Liotta LA.

Curr Protoc Cell Biol. 2001 May;Chapter 2:Unit 2.5. doi: 10.1002/0471143030.cb0205s10.

PMID:
18228350
41.

Overview of metastasis assays.

Paweletz CP, Charboneau L, Liotta LA.

Curr Protoc Cell Biol. 2001 Nov;Chapter 19:Unit 19.1. doi: 10.1002/0471143030.cb1901s12. Review.

PMID:
18228344
42.

Micro RT-PCR.

Paweletz CP, Charboneau L, Liotta LA.

Curr Protoc Cell Biol. 2001 May;Appendix 3:Appendix 3G. doi: 10.1002/0471143030.cba03gs10.

PMID:
18228289
43.

Protein microarray platforms for clinical proteomics.

Pollard HB, Srivastava M, Eidelman O, Jozwik C, Rothwell SW, Mueller GP, Jacobowitz DM, Darling T, Guggino WB, Wright J, Zeitlin PL, Paweletz CP.

Proteomics Clin Appl. 2007 Sep;1(9):934-52. doi: 10.1002/prca.200700154. Epub 2007 Aug 10.

PMID:
21136748
44.

Quantitative analysis of complex peptide mixtures using FTMS and differential mass spectrometry.

Meng F, Wiener MC, Sachs JR, Burns C, Verma P, Paweletz CP, Mazur MT, Deyanova EG, Yates NA, Hendrickson RC.

J Am Soc Mass Spectrom. 2007 Feb;18(2):226-33. Epub 2006 Oct 25.

45.

Surface enhanced laser desorption ionization spectrometry reveals biomarkers for drug treatment but not dose.

Paweletz CP, Wiener MC, Sachs JR, Meurer R, Wu MS, Wong KK, Yates NA, Hendrickson RC.

Proteomics. 2006 Apr;6(7):2101-7.

PMID:
16518871
46.

Proteomic analysis of human bladder tissue using SELDI approach following microdissection techniques.

Krieg RC, Gaisa NT, Paweletz CP, Knuechel R.

Methods Mol Biol. 2005;293:255-67. Review.

PMID:
16028425
47.

Identification and characterization of SSTK, a serine/threonine protein kinase essential for male fertility.

Spiridonov NA, Wong L, Zerfas PM, Starost MF, Pack SD, Paweletz CP, Johnson GR.

Mol Cell Biol. 2005 May;25(10):4250-61.

48.

Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays.

Charboneau L, Tory H, Chen T, Winters M, Petricoin EF 3rd, Liotta LA, Paweletz CP.

Brief Funct Genomic Proteomic. 2002 Oct;1(3):305-15. Review. Erratum in: Brief Funct Genomic Proteomic. 2007 Jun;6(2):159. Scott, Heather [corrected to Tory, Heather].

PMID:
15239896
49.

Signal pathway profiling of prostate cancer using reverse phase protein arrays.

Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF.

Proteomics. 2003 Nov;3(11):2142-6.

PMID:
14595813
50.

Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer.

Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF 3rd.

Proteomics. 2003 Sep;3(9):1801-10.

PMID:
12973739

Supplemental Content

Loading ...
Support Center